These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 1510424)
41. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Babé LM; Rosé J; Craik CS Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10069-73. PubMed ID: 7479728 [TBL] [Abstract][Full Text] [Related]
42. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. Zennou V; Mammano F; Paulous S; Mathez D; Clavel F J Virol; 1998 Apr; 72(4):3300-6. PubMed ID: 9525657 [TBL] [Abstract][Full Text] [Related]
43. Incorporation of functional human immunodeficiency virus type 1 integrase into virions independent of the Gag-Pol precursor protein. Liu H; Wu X; Xiao H; Conway JA; Kappes JC J Virol; 1997 Oct; 71(10):7704-10. PubMed ID: 9311854 [TBL] [Abstract][Full Text] [Related]
45. Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. Dukes CS; Matthews TJ; Lambert DM; Dreyer GB; Petteway SR; Weinberg JB AIDS Res Hum Retroviruses; 1996 Jun; 12(9):777-82. PubMed ID: 8738429 [TBL] [Abstract][Full Text] [Related]
46. trans-acting viral protease is necessary and sufficient for activation of avian leukosis virus reverse transcriptase. Stewart L; Vogt VM J Virol; 1991 Nov; 65(11):6218-31. PubMed ID: 1717719 [TBL] [Abstract][Full Text] [Related]
47. Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation. Novikova M; Adams LJ; Fontana J; Gres AT; Balasubramaniam M; Winkler DC; Kudchodkar SB; Soheilian F; Sarafianos SG; Steven AC; Freed EO mBio; 2018 Oct; 9(5):. PubMed ID: 30327442 [TBL] [Abstract][Full Text] [Related]
48. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Lindhofer H; von der Helm K; Nitschko H Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565 [TBL] [Abstract][Full Text] [Related]
49. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide. Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844 [TBL] [Abstract][Full Text] [Related]
50. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. Huang M; Orenstein JM; Martin MA; Freed EO J Virol; 1995 Nov; 69(11):6810-8. PubMed ID: 7474093 [TBL] [Abstract][Full Text] [Related]
51. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor. Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140 [TBL] [Abstract][Full Text] [Related]
52. Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. Sommerfelt MA; Petteway SR; Dreyer GB; Hunter E J Virol; 1992 Jul; 66(7):4220-7. PubMed ID: 1602542 [TBL] [Abstract][Full Text] [Related]
53. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. Kräusslich HG J Virol; 1992 Jan; 66(1):567-72. PubMed ID: 1727499 [TBL] [Abstract][Full Text] [Related]
54. Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease. Ross EK; Fuerst TR; Orenstein JM; O'Neill T; Martin MA; Venkatesan S AIDS Res Hum Retroviruses; 1991 May; 7(5):475-83. PubMed ID: 1873082 [TBL] [Abstract][Full Text] [Related]
55. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Nascimbeni M; Lamotte C; Peytavin G; Farinotti R; Clavel F Antimicrob Agents Chemother; 1999 Nov; 43(11):2629-34. PubMed ID: 10543739 [TBL] [Abstract][Full Text] [Related]
56. Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. Bukovsky AA; Dorfman T; Weimann A; Göttlinger HG J Virol; 1997 Feb; 71(2):1013-8. PubMed ID: 8995620 [TBL] [Abstract][Full Text] [Related]
57. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. Kotler M; Simm M; Zhao YS; Sova P; Chao W; Ohnona SF; Roller R; Krachmarov C; Potash MJ; Volsky DJ J Virol; 1997 Aug; 71(8):5774-81. PubMed ID: 9223465 [TBL] [Abstract][Full Text] [Related]
58. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain. Liao WH; Wang CT Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885 [TBL] [Abstract][Full Text] [Related]
59. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. Peng C; Ho BK; Chang TW; Chang NT J Virol; 1989 Jun; 63(6):2550-6. PubMed ID: 2657099 [TBL] [Abstract][Full Text] [Related]
60. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]